Moxifloxacino Sandoz (Moxifloxacin)

Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This dual inhibition disrupts bacterial DNA processes, leading to rapid bactericidal activity against a broad range of Gram‑positive and Gram‑negative pathogens.

The dosage regimen is determined by the prescribing clinician based on the specific infection, patient age, renal and hepatic function, and local resistance patterns. The prescriber selects the appropriate strength, frequency, and duration of therapy.

Safety in pregnancy and lactation has not been fully established; the drug should only be used when the potential benefit outweighs the potential risk to the fetus or infant. Clinicians should evaluate each case individually and consider alternative therapies when possible.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Moxifloxacin offers broader activity against Gram‑positive organisms and better coverage of atypical pathogens compared with older fluoroquinolones such as ciprofloxacin. Its pharmacokinetic profile allows once‑daily dosing, but it shares class‑related safety considerations that require careful patient selection.

Store the product at temperatures below 25 °C in its original container, protecting it from moisture and direct sunlight. Do not expose the tablets to excessive heat or humidity, and keep them out of reach of children.

The medication is taken orally, usually as a whole tablet with or without food, unless the prescribing information advises otherwise. Patients should swallow the tablet with a glass of water and follow the dosing schedule provided by their healthcare professional.

Serious adverse reactions can include tendon rupture, QT‑interval prolongation leading to cardiac arrhythmias, severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated diarrhea, hepatic toxicity, and peripheral neuropathy. Prompt medical attention is required if any of these events occur.

Patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, individuals with prolonged QT interval, and patients receiving concomitant medications that significantly prolong QT should avoid this drug unless no alternatives exist.